
Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
Patients underwent one night of a sham stimulation followed by pink noise stimulation delivered during slow wave activity.
Research published in
Patients underwent one night of a sham stimulation followed by pink noise stimulation delivered during slow wave activity. Verbal paired-associate memory was tested before and after sleep.
Researchers found that slow wave activity was enhanced on EEG and sleep-dependent memory storage was improved.




